Pub Date : 2023-07-03DOI: 10.1038/s41568-023-00594-2
Geniver El Tekle, Wendy S. Garrett
Cancer cells originate from a series of acquired genetic mutations that can drive their uncontrolled cell proliferation and immune evasion. Environmental factors, including the microorganisms that colonize the human body, can shift the metabolism, growth pattern and function of neoplastic cells and shape the tumour microenvironment. Dysbiosis of the gut microbiome is now recognized as a hallmark of cancer by the scientific community. However, only a few microorganisms have been identified that directly initiate tumorigenesis or skew the immune system to generate a tumour-permissive milieu. Over the past two decades, research on the human microbiome and its functionalities within and across individuals has revealed microbiota-focused strategies for health and disease. Here, we review the evolving understanding of the mechanisms by which the microbiota acts in cancer initiation, promotion and progression. We explore the roles of bacteria in gastrointestinal tract malignancies and cancers of the lung, breast and prostate. Finally, we discuss the promises and limitations of targeting or harnessing bacteria in personalized cancer prevention, diagnostics and treatment. The role of the microbiota in tumorigenesis has garnered considerable attention over the past two decades. In this Review, El Tekle and Garrett explore the current and evolving understanding of microbiota in cancers of various internal organs, as well as highlighting opportunities for targeting bacteria for cancer prevention, diagnostics and treatment.
{"title":"Bacteria in cancer initiation, promotion and progression","authors":"Geniver El Tekle, Wendy S. Garrett","doi":"10.1038/s41568-023-00594-2","DOIUrl":"10.1038/s41568-023-00594-2","url":null,"abstract":"Cancer cells originate from a series of acquired genetic mutations that can drive their uncontrolled cell proliferation and immune evasion. Environmental factors, including the microorganisms that colonize the human body, can shift the metabolism, growth pattern and function of neoplastic cells and shape the tumour microenvironment. Dysbiosis of the gut microbiome is now recognized as a hallmark of cancer by the scientific community. However, only a few microorganisms have been identified that directly initiate tumorigenesis or skew the immune system to generate a tumour-permissive milieu. Over the past two decades, research on the human microbiome and its functionalities within and across individuals has revealed microbiota-focused strategies for health and disease. Here, we review the evolving understanding of the mechanisms by which the microbiota acts in cancer initiation, promotion and progression. We explore the roles of bacteria in gastrointestinal tract malignancies and cancers of the lung, breast and prostate. Finally, we discuss the promises and limitations of targeting or harnessing bacteria in personalized cancer prevention, diagnostics and treatment. The role of the microbiota in tumorigenesis has garnered considerable attention over the past two decades. In this Review, El Tekle and Garrett explore the current and evolving understanding of microbiota in cancers of various internal organs, as well as highlighting opportunities for targeting bacteria for cancer prevention, diagnostics and treatment.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 9","pages":"600-618"},"PeriodicalIF":78.5,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10419693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-27DOI: 10.1038/s41568-023-00601-6
Daniela Senft
In this study, Malladi and colleagues reveal the mechanism by which mitochondrial fragmentation enables latent brain metastatic breast cancer cells to increase fatty acid oxidation to maintain cellular energetics and redox homeostasis.
{"title":"Feeding latent brain metastasis","authors":"Daniela Senft","doi":"10.1038/s41568-023-00601-6","DOIUrl":"10.1038/s41568-023-00601-6","url":null,"abstract":"In this study, Malladi and colleagues reveal the mechanism by which mitochondrial fragmentation enables latent brain metastatic breast cancer cells to increase fatty acid oxidation to maintain cellular energetics and redox homeostasis.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 8","pages":"510-510"},"PeriodicalIF":78.5,"publicationDate":"2023-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10250230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-23DOI: 10.1038/s41568-023-00600-7
Lisa M. Coussens, Michele De Palma, Samanta A. Mariani, Luca Cassetta
{"title":"Jeff Pollard (1950–2023)","authors":"Lisa M. Coussens, Michele De Palma, Samanta A. Mariani, Luca Cassetta","doi":"10.1038/s41568-023-00600-7","DOIUrl":"10.1038/s41568-023-00600-7","url":null,"abstract":"","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 8","pages":"507-507"},"PeriodicalIF":78.5,"publicationDate":"2023-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41568-023-00600-7.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10231909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-23DOI: 10.1038/s41568-023-00593-3
Mijin Kim, Magdalini Panagiotakopoulou, Chen Chen, Stephen B. Ruiz, Karuna Ganesh, Tuomas Tammela, Daniel A. Heller
The interactions among tumour cells, the tumour microenvironment (TME) and non-tumour tissues are of interest to many cancer researchers. Micro-engineering approaches and nanotechnologies are under extensive exploration for modelling these interactions and measuring them in situ and in vivo to investigate therapeutic vulnerabilities in cancer and extend a systemic view of tumour ecosystems. Here we highlight the greatest opportunities for improving the understanding of tumour ecosystems using microfluidic devices, bioprinting or organ-on-a-chip approaches. We also discuss the potential of nanosensors that can transmit information from within the TME or elsewhere in the body to address scientific and clinical questions about changes in chemical gradients, enzymatic activities, metabolic and immune profiles of the TME and circulating analytes. This Review aims to connect the cancer biology and engineering communities, presenting biomedical technologies that may expand the methodologies of the former, while inspiring the latter to develop approaches for interrogating cancer ecosystems. Tumour ecosystems encompass a multitude of variables, including enzymatic, metabolic and immune components within the tumour and across organs. This Review summarizes how micro-engineering approaches and nanosensors have been used to establish multicomponent tumour models and to assess tumour plasticity.
{"title":"Micro-engineering and nano-engineering approaches to investigate tumour ecosystems","authors":"Mijin Kim, Magdalini Panagiotakopoulou, Chen Chen, Stephen B. Ruiz, Karuna Ganesh, Tuomas Tammela, Daniel A. Heller","doi":"10.1038/s41568-023-00593-3","DOIUrl":"10.1038/s41568-023-00593-3","url":null,"abstract":"The interactions among tumour cells, the tumour microenvironment (TME) and non-tumour tissues are of interest to many cancer researchers. Micro-engineering approaches and nanotechnologies are under extensive exploration for modelling these interactions and measuring them in situ and in vivo to investigate therapeutic vulnerabilities in cancer and extend a systemic view of tumour ecosystems. Here we highlight the greatest opportunities for improving the understanding of tumour ecosystems using microfluidic devices, bioprinting or organ-on-a-chip approaches. We also discuss the potential of nanosensors that can transmit information from within the TME or elsewhere in the body to address scientific and clinical questions about changes in chemical gradients, enzymatic activities, metabolic and immune profiles of the TME and circulating analytes. This Review aims to connect the cancer biology and engineering communities, presenting biomedical technologies that may expand the methodologies of the former, while inspiring the latter to develop approaches for interrogating cancer ecosystems. Tumour ecosystems encompass a multitude of variables, including enzymatic, metabolic and immune components within the tumour and across organs. This Review summarizes how micro-engineering approaches and nanosensors have been used to establish multicomponent tumour models and to assess tumour plasticity.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 9","pages":"581-599"},"PeriodicalIF":78.5,"publicationDate":"2023-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10063471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-22DOI: 10.1038/s41568-023-00591-5
Qun Zeng, Mira Mousa, Aisha Shigna Nadukkandy, Lies Franssens, Halima Alnaqbi, Fatima Yousif Alshamsi, Habiba Al Safar, Peter Carmeliet
Anti-angiogenic therapies (AATs) are used to treat different types of cancers. However, their success is limited owing to insufficient efficacy and resistance. Recently, single-cell omics studies of tumour endothelial cells (TECs) have provided new mechanistic insight. Here, we overview the heterogeneity of human TECs of all tumour types studied to date, at the single-cell level. Notably, most human tumour types contain varying numbers but only a small population of angiogenic TECs, the presumed targets of AATs, possibly contributing to the limited efficacy of and resistance to AATs. In general, TECs are heterogeneous within and across all tumour types, but comparing TEC phenotypes across tumours is currently challenging, owing to the lack of a uniform nomenclature for endothelial cells and consistent single-cell analysis protocols, urgently raising the need for a more consistent approach. Nonetheless, across most tumour types, universal TEC markers (ACKR1, PLVAP and IGFBP3) can be identified. Besides angiogenesis, biological processes such as immunomodulation and extracellular matrix organization are among the most commonly predicted enriched signatures of TECs across different tumour types. Although angiogenesis and extracellular matrix targets have been considered for AAT (without the hoped success), the immunomodulatory properties of TECs have not been fully considered as a novel anticancer therapeutic approach. Therefore, we also discuss progress, limitations, solutions and novel targets for AAT development. In this Review, Zeng et al. describe the recent single-cell omics studies that have revealed the heterogeneity of human tumour endothelial cells and demonstrate that the phenotypes of these cells extend beyond that of simply being angiogenic, an observation that could be translated into the clinic to improve upon the success rate of current anti-angiogenic therapies.
{"title":"Understanding tumour endothelial cell heterogeneity and function from single-cell omics","authors":"Qun Zeng, Mira Mousa, Aisha Shigna Nadukkandy, Lies Franssens, Halima Alnaqbi, Fatima Yousif Alshamsi, Habiba Al Safar, Peter Carmeliet","doi":"10.1038/s41568-023-00591-5","DOIUrl":"10.1038/s41568-023-00591-5","url":null,"abstract":"Anti-angiogenic therapies (AATs) are used to treat different types of cancers. However, their success is limited owing to insufficient efficacy and resistance. Recently, single-cell omics studies of tumour endothelial cells (TECs) have provided new mechanistic insight. Here, we overview the heterogeneity of human TECs of all tumour types studied to date, at the single-cell level. Notably, most human tumour types contain varying numbers but only a small population of angiogenic TECs, the presumed targets of AATs, possibly contributing to the limited efficacy of and resistance to AATs. In general, TECs are heterogeneous within and across all tumour types, but comparing TEC phenotypes across tumours is currently challenging, owing to the lack of a uniform nomenclature for endothelial cells and consistent single-cell analysis protocols, urgently raising the need for a more consistent approach. Nonetheless, across most tumour types, universal TEC markers (ACKR1, PLVAP and IGFBP3) can be identified. Besides angiogenesis, biological processes such as immunomodulation and extracellular matrix organization are among the most commonly predicted enriched signatures of TECs across different tumour types. Although angiogenesis and extracellular matrix targets have been considered for AAT (without the hoped success), the immunomodulatory properties of TECs have not been fully considered as a novel anticancer therapeutic approach. Therefore, we also discuss progress, limitations, solutions and novel targets for AAT development. In this Review, Zeng et al. describe the recent single-cell omics studies that have revealed the heterogeneity of human tumour endothelial cells and demonstrate that the phenotypes of these cells extend beyond that of simply being angiogenic, an observation that could be translated into the clinic to improve upon the success rate of current anti-angiogenic therapies.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 8","pages":"544-564"},"PeriodicalIF":78.5,"publicationDate":"2023-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9873119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-15DOI: 10.1038/s41568-023-00597-z
Gabrielle Brewer
Wang et al. demonstrate how tumour-derived extracellular vesicles and particles dysregulate liver function to promote fatty liver disease and diminish chemotherapeutic efficacy.
Wang 等人展示了肿瘤衍生的细胞外囊泡和微粒如何使肝功能失调，从而促进脂肪肝并降低化疗疗效。
{"title":"Tumour EVPs disrupt liver function","authors":"Gabrielle Brewer","doi":"10.1038/s41568-023-00597-z","DOIUrl":"10.1038/s41568-023-00597-z","url":null,"abstract":"Wang et al. demonstrate how tumour-derived extracellular vesicles and particles dysregulate liver function to promote fatty liver disease and diminish chemotherapeutic efficacy.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 8","pages":"510-510"},"PeriodicalIF":78.5,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9927839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-15DOI: 10.1038/s41568-023-00596-0
Ciaran P. Seath
In this Tools of the Trade article, Ciaran Seath describes the development and use of a proximity labelling method to study how cancer driving mutations and small molecule ligands remodel the chromatin microenvironment.
在这篇 "贸易工具"（Tools of the Trade）文章中，Ciaran Seath 介绍了近距离标记法的开发和使用情况，以研究癌症驱动突变和小分子配体如何重塑染色质微环境。
{"title":"Proximity labelling to study chromatin interactomes","authors":"Ciaran P. Seath","doi":"10.1038/s41568-023-00596-0","DOIUrl":"10.1038/s41568-023-00596-0","url":null,"abstract":"In this Tools of the Trade article, Ciaran Seath describes the development and use of a proximity labelling method to study how cancer driving mutations and small molecule ligands remodel the chromatin microenvironment.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 9","pages":"577-577"},"PeriodicalIF":78.5,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10054161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-13DOI: 10.1038/s41568-023-00586-2
Chuang Liu, Qiangqiang Shi, Xiangang Huang, Seyoung Koo, Na Kong, Wei Tao
Due to the fact that mRNA technology allows the production of diverse vaccines and treatments in a shorter time frame and with reduced expense compared to conventional approaches, there has been a surge in the use of mRNA-based therapeutics in recent years. With the aim of encoding tumour antigens for cancer vaccines, cytokines for immunotherapy, tumour suppressors to inhibit tumour development, chimeric antigen receptors for engineered T cell therapy or genome-editing proteins for gene therapy, many of these therapeutics have shown promising efficacy in preclinical studies, and some have even entered clinical trials. Given the evidence supporting the effectiveness and safety of clinically approved mRNA vaccines, coupled with growing interest in mRNA-based therapeutics, mRNA technology is poised to become one of the major pillars in cancer drug development. In this Review, we present in vitro transcribed mRNA-based therapeutics for cancer treatment, including the characteristics of the various types of synthetic mRNA, the packaging systems for efficient mRNA delivery, preclinical and clinical studies, current challenges and future prospects in the field. We anticipate the translation of promising mRNA-based treatments into clinical applications, to ultimately benefit patients. mRNA for therapeutics is growing in popularity owing to the relative ease of synthesis and nucleotide alteration for personalized medicine. In this Review, Liu et al. outline the characteristics of in vitro transcribed mRNA-based therapeutics for cancer treatment, highlighting the ongoing clinical studies, current challenges and future opportunities.
{"title":"mRNA-based cancer therapeutics","authors":"Chuang Liu, Qiangqiang Shi, Xiangang Huang, Seyoung Koo, Na Kong, Wei Tao","doi":"10.1038/s41568-023-00586-2","DOIUrl":"10.1038/s41568-023-00586-2","url":null,"abstract":"Due to the fact that mRNA technology allows the production of diverse vaccines and treatments in a shorter time frame and with reduced expense compared to conventional approaches, there has been a surge in the use of mRNA-based therapeutics in recent years. With the aim of encoding tumour antigens for cancer vaccines, cytokines for immunotherapy, tumour suppressors to inhibit tumour development, chimeric antigen receptors for engineered T cell therapy or genome-editing proteins for gene therapy, many of these therapeutics have shown promising efficacy in preclinical studies, and some have even entered clinical trials. Given the evidence supporting the effectiveness and safety of clinically approved mRNA vaccines, coupled with growing interest in mRNA-based therapeutics, mRNA technology is poised to become one of the major pillars in cancer drug development. In this Review, we present in vitro transcribed mRNA-based therapeutics for cancer treatment, including the characteristics of the various types of synthetic mRNA, the packaging systems for efficient mRNA delivery, preclinical and clinical studies, current challenges and future prospects in the field. We anticipate the translation of promising mRNA-based treatments into clinical applications, to ultimately benefit patients. mRNA for therapeutics is growing in popularity owing to the relative ease of synthesis and nucleotide alteration for personalized medicine. In this Review, Liu et al. outline the characteristics of in vitro transcribed mRNA-based therapeutics for cancer treatment, highlighting the ongoing clinical studies, current challenges and future opportunities.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 8","pages":"526-543"},"PeriodicalIF":78.5,"publicationDate":"2023-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.nature.com/articles/s41568-023-00586-2.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10250209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-12DOI: 10.1038/s41568-023-00579-1
J. Matthew Franklin, Zhengming Wu, Kun-Liang Guan
Decades of research have mapped out the basic mechanics of the Hippo pathway. The paralogues Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), as the central transcription control module of the Hippo pathway, have long been implicated in the progression of various human cancers. The current literature regarding oncogenic YAP and TAZ activities consists mostly of context-specific mechanisms and treatments of human cancers. Furthermore, a growing number of studies demonstrate tumour-suppressor functions of YAP and TAZ. In this Review we aim to synthesize an integrated perspective of the many disparate findings regarding YAP and TAZ in cancer. We then conclude with the various strategies for targeting and treating YAP- and TAZ-dependent cancers. The activities of YAP and TAZ have long been associated with cancer progression. In this Review, Franklin et al. provide an integrated perspective on the latest understandings of YAP and TAZ activation, including their role as a tumour suppressor, as well as advances in YAP and TAZ therapeutic treatments.
{"title":"Insights into recent findings and clinical application of YAP and TAZ in cancer","authors":"J. Matthew Franklin, Zhengming Wu, Kun-Liang Guan","doi":"10.1038/s41568-023-00579-1","DOIUrl":"10.1038/s41568-023-00579-1","url":null,"abstract":"Decades of research have mapped out the basic mechanics of the Hippo pathway. The paralogues Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ), as the central transcription control module of the Hippo pathway, have long been implicated in the progression of various human cancers. The current literature regarding oncogenic YAP and TAZ activities consists mostly of context-specific mechanisms and treatments of human cancers. Furthermore, a growing number of studies demonstrate tumour-suppressor functions of YAP and TAZ. In this Review we aim to synthesize an integrated perspective of the many disparate findings regarding YAP and TAZ in cancer. We then conclude with the various strategies for targeting and treating YAP- and TAZ-dependent cancers. The activities of YAP and TAZ have long been associated with cancer progression. In this Review, Franklin et al. provide an integrated perspective on the latest understandings of YAP and TAZ activation, including their role as a tumour suppressor, as well as advances in YAP and TAZ therapeutic treatments.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 8","pages":"512-525"},"PeriodicalIF":78.5,"publicationDate":"2023-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9920428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-07DOI: 10.1038/s41568-023-00590-6
Isabel Esain-Garcia
In this Tools of the Trade article, Isabel Esain-Garcia describes the development and use of a 6-letter whole-genome sequencing technology, which enables the simultaneous acquisition of genetic and epigenetic information from human genomic and cell-free DNA, which has implications for improving our biological understanding of cancer as well as cancer diagnosis and early intervention.
在这篇 "贸易工具"（Tools of the Trade）文章中，伊莎贝尔-埃塞因-加西亚（Isabel Esain-Garcia）介绍了6字母全基因组测序技术的开发和使用情况，该技术可同时从人类基因组和无细胞DNA中获取遗传和表观遗传信息，对提高我们对癌症的生物学认识以及癌症诊断和早期干预具有重要意义。
{"title":"Deciphering the cancer genome and epigenome","authors":"Isabel Esain-Garcia","doi":"10.1038/s41568-023-00590-6","DOIUrl":"10.1038/s41568-023-00590-6","url":null,"abstract":"In this Tools of the Trade article, Isabel Esain-Garcia describes the development and use of a 6-letter whole-genome sequencing technology, which enables the simultaneous acquisition of genetic and epigenetic information from human genomic and cell-free DNA, which has implications for improving our biological understanding of cancer as well as cancer diagnosis and early intervention.","PeriodicalId":19055,"journal":{"name":"Nature Reviews Cancer","volume":"23 8","pages":"509-509"},"PeriodicalIF":78.5,"publicationDate":"2023-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10250197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：